

VIZIONFOCUS INC.
and subsidiaries

**Consolidated Financial Statements and
Independent Auditors' Review Report
Q1 of 2025 and 2024**

Address: 3F, No. 66, Youyi Road, Zhunan Township,
Miaoli County
Tel: (037) 582900

Independent Auditors' Review Report

To VIZIONFOCUS INC.:

Foreword

The consolidated balance sheets of VIZIONFOCUS INC. and its subsidiaries as of March 31 for the years 2025 and 2024, as well as the consolidated comprehensive income statements, consolidated statements of changes in equity, consolidated cash flow statements, and notes to the consolidated financial statements (including a summary of significant accounting policies) for the period from January 1 to March 31 for the years 2025 and 2024, have been reviewed by our accountants. The preparation of consolidated financial statements that present fairly the Company's consolidated financial position, financial performance, and cash flows in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission is the responsibility of the Company's management. Our responsibility is to express a conclusion on these consolidated financial statements based on our review.

Scope

We conducted our review in accordance with International Standard on Review Engagements No. 2410 "Review of Financial Statements." The procedures performed in a review of consolidated financial statements consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Therefore, we do not express an audit opinion.

Conclusion

Based on the review results of the accountant, no matters have been identified that would cause the aforementioned financial statements to not present fairly, in all material respects, the consolidated financial position of VIZIONFOCUS INC. (the "Company") and its subsidiaries as of March 31, 2025 and 2024, and their consolidated financial performance and consolidated cash flows for the three months ended March 31, 2025 and 2024, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission.

The engagement partners on the reviews resulting in this independent auditors' review report are Hsiu-Wen Chen and Yao-Lin Huang.

Deloitte & Touche
Taipei, Taiwan
Republic of China

May 5, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.

VIZIONFOCUS INC. and subsidiaries
Consolidated Balance Sheet
March 31, 2025, December 31, 2024 and March 31, 2024

Code	Assets	March 31, 2025		December 31, 2024		Unit: NTD Thousand March 31, 2024	
		Amount	%	Amount	%	Amount	%
	Current assets						
1100	Cash and cash equivalents (Note 6)	\$ 1,294,075	20	\$ 1,180,126	20	\$ 1,796,329	32
1150	Notes receivable (Note 8)	3,072	-	8,514	-	12,585	-
1170	Accounts receivable (Note 8)	647,800	10	632,907	11	557,538	10
1200	Other receivables	10,720	-	1,700	-	4,987	-
1220	Current income tax assets	10,380	-	6,172	-	9,810	-
130X	Inventories (Note 9)	294,083	5	288,598	5	275,006	5
1410	Prepayments	63,481	1	59,448	1	48,658	1
1476	Other financial assets – current (Note 7 & 30)	329,432	5	253,800	4	-	-
1479	Other current assets	254	-	215	-	1,378	-
11XX	Total current assets	<u>2,653,297</u>	<u>41</u>	<u>2,431,480</u>	<u>41</u>	<u>2,706,291</u>	<u>48</u>
	Non-current assets						
1600	Property, plant and equipment (Notes 11, 29 & 30)	3,152,278	51	2,995,474	51	2,481,134	46
1755	Right-of-use assets (Note 12)	354,227	6	353,720	6	199,322	4
1780	Intangible assets (Note 13)	131,802	2	112,676	2	80,976	1
1840	Deferred income tax assets	7,614	-	9,407	-	9,391	-
1915	Prepayment for equipment (Note 29)	31,701	-	24,466	-	58,664	1
1920	Refundable deposits (Note 29)	12,882	-	12,424	-	6,529	-
1990	Other non-current assets	-	-	64	-	256	-
15XX	Total non-current assets	<u>3,690,504</u>	<u>59</u>	<u>3,508,231</u>	<u>59</u>	<u>2,836,272</u>	<u>52</u>
1XXX	Total assets	<u>\$ 6,343,801</u>	<u>100</u>	<u>\$ 5,939,711</u>	<u>100</u>	<u>\$ 5,542,563</u>	<u>100</u>
	Liabilities and equity						
	Current liabilities						
2130	Contract liabilities – Current (Note 19)	\$ 7,931	-	\$ 4,384	-	\$ 4,691	-
2170	Accounts payable (Note 15)	197,550	3	194,453	3	182,185	3
2200	Other payables (Notes 16 & 29)	343,715	5	336,152	6	339,576	6
2230	Current income tax liabilities	108,566	2	66,412	1	82,914	1
2280	Lease liabilities – current (Notes 12 & 29)	50,088	1	48,588	1	32,907	1
2313	Deferred revenue (Notes 14 & 24)	4,017	-	4,107	-	6,080	-
2322	Long-term borrowings due within one year (Notes 14, 29 & 30)	155,279	2	156,078	3	186,601	3
2399	Other current liabilities	207	-	434	-	3,798	-
21XX	Total current liabilities	<u>867,353</u>	<u>13</u>	<u>810,608</u>	<u>14</u>	<u>838,752</u>	<u>14</u>
	Non-current liabilities						
2540	Long-term borrowings (Notes 14, 29 & 30)	881,044	15	819,457	14	949,638	18
2570	Deferred income tax liabilities	148,396	2	138,820	2	99,666	2
2580	Lease liabilities – non-current (Notes 12 & 29)	310,819	5	311,051	5	175,696	3
2630	Long-term deferred revenue (Notes 14 & 24)	9,102	-	8,463	-	11,522	-
2640	Net defined benefit liabilities (Notes 4 & 17)	1,646	-	1,478	-	851	-
2670	Other non-current liabilities	242	-	237	-	234	-
25XX	Total non-current liabilities	<u>1,351,249</u>	<u>22</u>	<u>1,279,506</u>	<u>21</u>	<u>1,237,607</u>	<u>23</u>
2XXX	Total liabilities	<u>2,218,602</u>	<u>35</u>	<u>2,090,114</u>	<u>35</u>	<u>2,076,359</u>	<u>37</u>
	Equity attributable to owners of the Company (Note 18)						
	Capital stock						
3110	Common stock capital	580,447	9	579,247	10	575,117	10
3140	Advance Receipts for Share Capital	-	-	5,498	-	-	-
3100	Total Share Capital	<u>580,447</u>	<u>9</u>	<u>584,745</u>	<u>10</u>	<u>575,117</u>	<u>10</u>
3200	Capital reserve	<u>1,841,333</u>	<u>29</u>	<u>1,828,095</u>	<u>31</u>	<u>1,816,968</u>	<u>33</u>
	Retained earnings						
3310	Statutory Reserve	82,650	1	82,650	1	55,501	1
3320	Special reserves	9,499	-	9,499	-	-	-
3350	Undistributed earnings	<u>1,201,202</u>	<u>19</u>	<u>1,008,471</u>	<u>18</u>	<u>745,794</u>	<u>14</u>
3300	Total retained earnings	<u>1,293,351</u>	<u>20</u>	<u>1,100,620</u>	<u>19</u>	<u>801,295</u>	<u>15</u>
3400	Other equity						
3410	Foreign Currency Translation Adjustment	<u>41,371</u>	<u>1</u>	<u>19,275</u>	<u>-</u>	<u>5,809</u>	<u>-</u>
31XX	Total owners' equity of the Company	<u>3,756,502</u>	<u>59</u>	<u>3,532,735</u>	<u>60</u>	<u>3,199,189</u>	<u>58</u>
36XX	Non-controlling interests (Notes 10 & 18)	<u>368,697</u>	<u>6</u>	<u>316,862</u>	<u>5</u>	<u>267,015</u>	<u>5</u>
3XXX	Total equity	<u>4,125,199</u>	<u>65</u>	<u>3,849,597</u>	<u>65</u>	<u>3,466,204</u>	<u>63</u>
3X2X	Total liabilities and equity	<u>\$ 6,343,801</u>	<u>100</u>	<u>\$ 5,939,711</u>	<u>100</u>	<u>\$ 5,542,563</u>	<u>100</u>

The accompanying notes are an integral part of the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Consolidated Statement of Comprehensive Income
For the years ended March 31, 2025 and 2024

Unit: NT\$ thousand,
except for earnings per share

Code		January 1 to March 31, 2025		January 1 to March 31, 2024	
		Amount	%	Amount	%
4000	Net operating revenue (Note 19)	\$ 810,535	100	\$ 768,033	100
5000	Operating costs (Notes 9, 20 & 29)	<u>474,747</u>	<u>59</u>	<u>457,678</u>	<u>60</u>
5900	Gross operating profit	<u>335,788</u>	<u>41</u>	<u>310,355</u>	<u>40</u>
	Operating expenses (Notes 8 & 20)				
6100	Sales promotion expenses	20,107	2	13,936	2
6200	Administrative expenses	36,757	5	30,939	3
6300	R&D expenses	40,235	5	35,930	5
6450	Expected Credit Losses (Reversal Gains)	<u>206</u>	<u>-</u>	<u>(9,565)</u>	<u>(1)</u>
6000	Total operating expenses	<u>97,305</u>	<u>12</u>	<u>71,240</u>	<u>9</u>
6900	Net operating profit	<u>238,483</u>	<u>29</u>	<u>239,115</u>	<u>31</u>
	Non-operating income and expenses (Note 20 & 29)				
7100	Interest revenue	3,464	-	3,539	-
7010	Other income	10,191	2	4,487	1
7020	Other gains and losses	10,809	2	13,546	2
7050	Finance Costs	<u>(6,675)</u>	<u>(1)</u>	<u>(7,330)</u>	<u>(1)</u>
7000	Total non-operating income and expenses	<u>17,789</u>	<u>3</u>	<u>14,242</u>	<u>2</u>
7900	Net income before tax	256,272	32	253,357	33
7950	Income tax expense (Note 4 & 21)	<u>54,956</u>	<u>7</u>	<u>56,784</u>	<u>7</u>
8200	Net income for the period	<u>201,316</u>	<u>25</u>	<u>196,573</u>	<u>26</u>

(To be Continued)

(Continued from previous page)

Code		January 1 to March 31, 2025		January 1 to March 31, 2024	
		Amount	%	Amount	%
8300	Other comprehensive income (Notes 18 & 21)				
8360	Items that may be reclassified subsequently to profit or loss				
8361	Foreign Currency Translation Adjustment	\$ 34,479	4	\$ 23,919	3
8399	Income tax related to items that may be reclassified	<u>(5,524)</u>	<u>(1)</u>	<u>(3,827)</u>	<u>-</u>
8300	Other comprehensive income for the period (net amount after tax)	<u>28,955</u>	<u>3</u>	<u>20,092</u>	<u>3</u>
8500	Total comprehensive income for the period	<u>\$ 230,271</u>	<u>28</u>	<u>\$ 216,665</u>	<u>29</u>
	Net profit attributable to				
8610	Owners of the Company	\$ 192,731	24	\$ 182,829	24
8620	Non-controlling interests	<u>8,585</u>	<u>1</u>	<u>13,744</u>	<u>2</u>
8600		<u>\$ 201,316</u>	<u>25</u>	<u>\$ 196,573</u>	<u>26</u>
	Total comprehensive income attributable to				
8710	Owners of the Company	\$ 214,827	26	\$ 198,137	27
8720	Non-controlling interests	<u>15,444</u>	<u>2</u>	<u>18,528</u>	<u>2</u>
8700		<u>\$ 230,271</u>	<u>28</u>	<u>\$ 216,665</u>	<u>29</u>
	Earnings per share (Note 22)				
9710	Basic	<u>\$ 3.32</u>		<u>\$ 3.42</u>	
9810	Diluted	<u>\$ 3.27</u>		<u>\$ 3.34</u>	

The accompanying notes are an integral part of the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Consolidated Statement of Changes in Equity
For the years ended March 31, 2025 and 2024

Unit: NTD Thousand

		Equity attributable to owners of the Company							Other equity				
Code		Capital stock			Capital reserve	Retained earnings			Foreign Currency Translation Adjustment	Total	Non-controlling interests	Total equity	
		Common stock capital	Advance Receipts for Share Capital	Total		Statutory Reserve	Special reserves	Undistributed earnings					Total
A1	Balance on January 1, 2025	\$ 579,247	\$ 5,498	\$ 584,745	\$ 1,828,095	\$ 82,650	\$ 9,499	\$ 1,008,471	\$ 1,100,620	\$ 19,275	\$ 3,532,735	\$ 316,862	\$ 3,849,597
D1	Net income for the three months ended March 31, 2025	-	-	-	-	-	-	192,731	192,731	-	192,731	8,585	201,316
D3	Other comprehensive income after tax from January 1 to March 31, 2025	-	-	-	-	-	-	-	-	22,096	22,096	6,859	28,955
D5	Total comprehensive income for the three months ended March 31, 2025	-	-	-	-	-	-	192,731	192,731	22,096	214,827	15,444	230,271
M5	Difference Between the Fair Value and Carrying Amount of the Consideration Paid or Received for the Acquisition or Disposal of Subsidiaries (Note 25)	-	-	-	29	-	-	-	-	-	29	35,571	35,600
N1	Share-based payment transactions (Notes 18 & 23)	1,200	(5,498)	(4,298)	13,209	-	-	-	-	-	8,911	-	8,911
O1	Increase of non-controlling interests (Note 18)	-	-	-	-	-	-	-	-	-	-	820	820
Z1	Balance on March 31, 2025	\$ 580,447	\$ -	\$ 580,447	\$ 1,841,333	\$ 82,650	\$ 9,499	\$ 1,201,202	\$ 1,293,351	\$ 41,371	\$ 3,756,502	\$ 368,697	\$ 4,125,199
A1	Balance on January 1, 2024	\$ 524,547	\$ -	\$ 524,547	\$ 653,674	\$ 55,501	\$ -	\$ 562,965	\$ 618,466	\$ (9,499)	\$ 1,787,188	\$ 248,487	\$ 2,035,675
D1	Net income for the three months ended March 31, 2024	-	-	-	-	-	-	182,829	182,829	-	182,829	13,744	196,573
D3	Other comprehensive income after tax from January 1 to March 31, 2024	-	-	-	-	-	-	-	-	15,308	15,308	4,784	20,092
D5	Total comprehensive income for the three months ended March 31, 2024	-	-	-	-	-	-	182,829	182,829	15,308	198,137	18,528	216,665
E1	Capital increase in cash (Note 18)	50,570	-	50,570	1,144,693	-	-	-	-	-	1,195,263	-	1,195,263
N1	Share-based payment transactions (Note 23)	-	-	-	21,601	-	-	-	-	-	21,601	-	21,601
T1	Cost of share issuance (Note 18)	-	-	-	(3,000)	-	-	-	-	-	(3,000)	-	(3,000)
Z1	Balance on March 31, 2024	\$ 575,117	\$ -	\$ 575,117	\$ 1,816,968	\$ 55,501	\$ -	\$ 745,794	\$ 801,295	\$ 5,809	\$ 3,199,189	\$ 267,015	\$ 3,466,204

The accompanying notes are an integral part of the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Consolidated Statements of Cash Flows
For the years ended March 31, 2025 and 2024

Unit: NTD Thousand

<u>Code</u>		<u>January 1 to March 31, 2025</u>	<u>January 1 to March 31, 2024</u>
	Cash flow from operating activities		
A10000	Net income before tax for the period	\$ 256,272	\$ 253,357
A20010	Income and expenses		
A20100	Depreciation expense	94,216	80,197
A20200	Amortization expense	3,709	3,375
A20300	Expected Credit Losses (Reversal Gains)	206	(9,565)
A20900	Finance Costs	6,675	7,330
A21200	Interest revenue	(3,464)	(3,539)
A21900	Share-based payment for remuneration	680	21,601
A22500	Gains from the disposal of property, plant and equipment	(25)	-
A23700	Loss on inventory valuation and obsolescence	6,470	359
A29900	Inventory Write-off Loss	33	438
A29900	Amortization of deferred income	(1,050)	(1,823)
A30000	Net changes in operating assets and liabilities		
A31130	Notes receivable	5,442	(4,320)
A31150	Accounts receivable	(15,128)	64,816
A31180	Other receivables	(8,949)	(3,019)
A31200	Inventories	(12,055)	(18,901)
A31230	Prepayments	(4,033)	15,719
A31240	Other current assets	(39)	(1,310)
A31990	Other non-current assets	64	63
A32125	Contract liabilities	3,547	(1,588)
A32150	Accounts payable	3,097	(42)
A32180	Other payables	(5,693)	(8,183)
A32230	Other current liabilities	(227)	(1,216)
A32240	Net defined benefit liabilities	168	116
A32990	Other non-current liabilities	<u>5</u>	<u>5</u>
A33000	Cash inflow from operations	329,921	393,870
A33100	Interest received	3,393	5,784
A33300	Interest paid	(5,572)	(5,586)
A33500	Income tax paid	<u>(12,112)</u>	<u>(4,657)</u>
AAAA	Net cash inflow from operating activities	<u>315,630</u>	<u>389,411</u>

(To be Continued)

(Continued from previous page)

Code		January 1 to March 31, 2025	January 1 to March 31, 2024
	Cash flow from investing activities		
B02700	Purchase of property, plant and equipment	\$ (210,682)	\$ (198,131)
B02800	Proceeds from the disposal of property, plant and equipment	25	
B03700	Increase in refundable deposits	(458)	(450)
B04500	Acquisition of intangible assets	(20,993)	(3,444)
B06500	Increase of other financial assets	<u>(75,632)</u>	<u>-</u>
BBBB	Net cash outflow from investing activities	<u>(307,740)</u>	<u>(202,025)</u>
	Cash flow from financing activities		
C00100	Increase in short-term borrowings	-	30,000
C00200	Decrease in short-term borrowings	-	(180,000)
C01600	Borrowing of long-term loans	101,820	319,933
C01700	Repayment of long-term borrowings	(40,483)	(554,425)
C04020	Lease principal repayment	(12,005)	(7,706)
C04600	Capital increase in cash	-	1,195,263
C04800	Exercise of employee stock options	8,231	-
C05800	Changes in non-controlling interests	35,600	-
C09900	Share issuance cost	<u>-</u>	<u>(3,000)</u>
CCCC	Net cash inflow from financing activities	<u>93,163</u>	<u>800,065</u>
DDDD	Effect of exchange rate changes on cash and cash equivalents	<u>12,896</u>	<u>8,722</u>
EEEE	Net increase in cash and cash equivalents	113,949	996,173
E00100	Opening balance of cash and cash equivalents	<u>1,180,126</u>	<u>800,156</u>
E00200	Closing balance of cash and cash equivalents	<u>\$ 1,294,075</u>	<u>\$ 1,796,329</u>

The accompanying notes are an integral part of the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Notes to the consolidated financial statements
For the years ended March 31, 2025 and 2024
(expressed in thousand NTD, Unless Stated Otherwise)

I. Company history

The Company was established in May 2012, mainly engaged in the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments and international trading, and other consulting services.

The Company has been listed and traded on the Taiwan Stock Exchange since March 2024.

The consolidated financial statements are presented in the Company’s functional currency, NTD.

II. Date and procedure for adopting financial statements

This consolidated financial statement was released after being approved by the Board of Directors on May 5, 2025.

III. Application of new and amended standards and interpretations

(I) The initial application of International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), interpretations (IFRIC), and interpretation announcements (SIC) approved and issued by the Financial Supervisory Commission (referred to as ‘IFRS accounting standards’).

The application of the amendments to the IFRSs endorsed and issued into effect by the FSC does not have material impact on the Company’s and its subsidiaries’ accounting policies.

(II) IFRS accounting standards approved by the FSC applicable in 2026

New/amended/revised standards and interpretations	Effective date announced by the International Accounting Standards Board (IASB)
Amendments to IFRS 9 and IFRS 7 “Classification and Measurement of Financial Instruments” regarding revisions to application guidance on financial asset classification	January 1, 2026 (Note)

Note : Applicable to annual reporting periods beginning on or after January 1, 2026; entities may also elect early adoption on January 1, 2025.

As of the date the Board of Directors approved and authorized the release of these consolidated financial statements, the Company and its subsidiaries continue to assess the impact of such amendments on financial position and financial performance.

(III) IFRS accounting standards issued by the IASB but not yet endorsed and issued into effect by the FSC

New/amended/revised standards and interpretations	Effective date announced by IASB (Note)
“Annual Improvements to IFRS Standards – Volume 11”	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Classification and Measurement of Financial Instruments” regarding revisions to application guidance on financial liability derecognition	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Contracts with Nature-Dependent Electricity”	January 1, 2026
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be determined
IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17	January 1, 2023
Amendments to IFRS 17 “Initial Application of IFRS 17 and IFRS 9 - Comparative Information”	January 1, 2023
IFRS 18 “Presentation and Disclosures of Financial Statements”	January 1, 2027
IFRS 19 “Subsidiary without Public Accountability: Disclosures”	January 1, 2027

Note : Unless stated otherwise, the above new IFRSs are effective for annual periods beginning on or after their respective effective dates.

IFRS 18 “Presentation and Disclosures of Financial Statements”

IFRS 18 will replace IAS 1 “Presentation of Financial Statements.” The main changes include:

- The income statement should classify revenue and expense items into operating, investing, financing, income tax, and discontinued operations categories.
- The income statement should present operating profit or loss, profit or loss before financing and taxes, as well as subtotals and totals of profit or loss.
- Providing guidance to enhance aggregation and disaggregation requirements: The Company and its subsidiaries shall identify assets, liabilities, equity, income, expenses, and cash flows of individual transactions or other events, and classify and aggregate them based on shared characteristics, so that each line item presented in the primary financial statements possesses at least one similar characteristic. Items of dissimilar nature should be presented separately in the primary financial statements and notes. The Company and its subsidiaries shall label items as "other" only when they cannot find more informative labels.
- Enhanced disclosure of management-defined performance measures: When the Company and its subsidiaries communicate publicly outside the financial statements and communicate management's view of a particular aspect of the overall financial performance to users of financial statements, they should disclose information related to management-defined performance measures in a single note to the financial statements, including a description of the

measure, how it is calculated, its reconciliation with subtotals or totals specified in IFRS accounting standards, and the income tax and non-controlling interest effects of related reconciling items.

Apart from the aforementioned impacts, as of the approval date of these consolidated financial statements by the Board of Directors, the Company and its subsidiaries are still evaluating the impact of amendments to other standards and interpretations on their financial position and performance. The relevant impacts will be disclosed upon completion of the assessment.

IV. Summary of significant accounting policies

(I) Compliance Statement

This consolidated financial statement has been prepared in conformity with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34 “Interim Financial Reporting” as endorsed by the Financial Supervisory Commission. These consolidated financial statements do not include all IFRS disclosures required for full annual consolidated financial statements.

(II) Basis of preparation

Except for the financial instruments measured at fair value and the net defined benefit liabilities recognized based on the present value of the defined benefit obligation less the fair value of plan assets, this consolidated financial statement has been prepared on the basis of historical cost.

The fair value is divided into Level 1 to Level 3 according to the observable degree and importance of the relevant input value:

1. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities available on the measurement date.
2. Level 2 inputs: Inputs, other than quoted prices in Level 1, that are observable, either directly (i.e., prices) or indirectly (i.e., derived from prices) for the asset or liability.
3. Level 3 inputs are unobservable inputs for the asset or liability.

(III) Basis of consolidation

This consolidated financial statement contains the financial statements of the Company and the entities (subsidiaries) controlled by the Company.

The financial statements of the subsidiaries have been properly adjusted to make their accounting policies consistent with the Company’s accounting policies. In preparing the consolidated financial statements, all intra-group transactions, account balances, income, and expenses have been eliminated. The total comprehensive income of the subsidiaries is attributed to the owners of the Company and non-controlling interests.

Changes in the Company’s ownership interests in subsidiaries that do not result in a loss of control are accounted for as equity transactions. The book value of the Company’s and its subsidiaries’ and non-controlling interests have been adjusted to reflect the changes in their relative interests in the subsidiaries. The difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the Company.

For details on subsidiaries, ownership percentages, and business activities, refer to Notes 10 and Tables 1 and 2.

(IV) Other significant accounting policies

Except for the following explanations, please refer to the summary of significant accounting policies in the 2024 annual consolidated financial statements.

1. Retirement benefits

Interim period pension costs are calculated on a year-to-date basis using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market volatility, plan amendments, curtailments and other significant one-time events during the interim period, if any.

2. Income tax expense

Income tax expense represents the sum of current income tax and deferred income tax. Interim period income tax expense is accrued based on the estimated average annual effective tax rate applied to the pre-tax income for the interim period.

V. Major sources of uncertainty in major accounting judgments, estimates, and assumptions

The significant accounting judgments, estimates and sources of estimation uncertainty applied in these consolidated financial statements are consistent with those of the 2024 annual consolidated financial statements.

VI. Cash and cash equivalents

	March 31, 2025	December 31, 2024	March 31, 2024
Cash on hands	\$ 160	\$ 146	\$ 257
Checks and demand deposits	753,915	760,802	946,072
Cash equivalents (investment with original maturity date of less than 3 months)			
Time deposits in banks	540,000	270,000	650,000
Commercial paper	-	100,000	200,000
Repurchase agreements	-	49,178	-
	<u>\$ 1,294,075</u>	<u>\$ 1,180,126</u>	<u>\$ 1,796,329</u>

VII. Other financial assets – current

	March 31, 2025	December 31, 2024	March 31, 2024
Time deposits with original maturity exceeding 3 months	\$ 327,145	\$ 253,800	\$ -
Pledged time deposits (Note 30)	<u>2,287</u>	<u>-</u>	<u>-</u>
	<u>\$ 329,432</u>	<u>\$ 253,800</u>	<u>\$ -</u>
Interest rate per annum (%)	1.35~2	1.445~2.05	-

VIII. Notes and accounts receivable

	March 31, 2025	December 31, 2024	March 31, 2024
Notes receivable			
Total book value measured at amortized cost - due to operations	<u>\$ 3,072</u>	<u>\$ 8,514</u>	<u>\$ 12,585</u>
Accounts receivable			
Total book value measured at amortized cost	\$ 649,508	\$ 634,380	\$ 564,950
Less: Loss allowance	<u>1,708</u>	<u>1,473</u>	<u>7,412</u>
	<u>\$ 647,800</u>	<u>\$ 632,907</u>	<u>\$ 557,538</u>

The Company and its subsidiaries recognize the loss allowance for accounts receivable based on the lifetime expected credit losses. The lifetime expected credit losses are calculated using a provision matrix, which takes into account customers' past collection experience, increase in delayed payments beyond the credit period, industry economic conditions and outlook. If there is evidence indicating that a transaction party is experiencing severe financial difficulties, and the company and its subsidiaries cannot reasonably expect to recover the amounts due—for instance, if the transaction party is undergoing liquidation or the debt has become overdue—the company and its subsidiaries will proceed according to its internal policy for managing abnormal receivables. The relevant receivables are directly written off, although collection efforts will continue. Any amounts recovered through these efforts will be recognized in the profit and loss statement.

The Company and subsidiaries continuously monitor collections to ensure that appropriate actions are taken for the recovery of overdue amounts. Additionally, on the balance sheet date, each receivable's recoverable amount is reviewed to ensure that adequate allowances for doubtful accounts have been provided for receivables that cannot be recovered.

The Company and subsidiaries measure the allowance for doubtful accounts on accounts receivable using a provision matrix, which is as follows:

March 31, 2025

	Not past due	Overdue 1 to 30 days	Overdue 31 to 120 days	Overdue 121 to 360 days	Overdue over 360 days	Counterparty shows signs of default	Total
Expected credit loss rate (%)	-	4	4	4	100	100	
Gross carrying amount	\$ 634,094	\$ 9,877	\$ 7,193	\$ -	\$ -	\$ 1,416	\$ 652,580
Allowance for losses (lifetime expected credit losses)	-	(75)	(266)	-	-	(1,367)	(1,708)
Amortized cost	<u>\$ 634,094</u>	<u>\$ 9,802</u>	<u>\$ 6,927</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 49</u>	<u>\$ 650,872</u>

December 31, 2024

	Not past due	Overdue 1 to 30 days	Overdue 31 to 120 days	Overdue 121 to 360 days	Overdue over 360 days	Counterparty shows signs of default	Total
Expected credit loss rate (%)	-	4	4~5	4~5	100	100	
Gross carrying amount	\$ 638,552	\$ 2,678	\$ -	\$ -	\$ -	\$ 1,664	\$ 642,894
Allowance for losses (lifetime expected credit losses)	-	-	-	-	-	(1,473)	(1,473)
Amortized cost	\$ 638,552	\$ 2,678	\$ -	\$ -	\$ -	\$ 191	\$ 641,421

March 31, 2024

	Not past due	Overdue 1 to 30 days	Overdue 31 to 120 days	Overdue 121 to 360 days	Overdue over 360 days	Counterparty shows signs of default	Total
Expected credit loss rate (%)	-	4	4~5	4~5	100	4~100	
Gross carrying amount	\$ 569,894	\$ -	\$ -	\$ -	\$ -	\$ 7,641	\$ 577,535
Allowance for losses (lifetime expected credit losses)	-	-	-	-	-	(7,412)	(7,412)
Amortized cost	\$ 569,894	\$ -	\$ -	\$ -	\$ -	\$ 229	\$ 570,123

Information on changes in loss allowance of accounts receivable is as follows:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Opening balance	\$ 1,473	\$ 16,860
Current period provision (reversal)	206	(9,565)
Exchange rate effect	29	117
Closing balance	\$ 1,708	\$ 7,412

IX. Inventories

	March 31, 2025	December 31, 2024	March 31, 2024
Raw materials	\$ 59,142	\$ 51,084	\$ 41,499
Materials	36,340	34,379	29,270
Work in process	44,945	51,967	21,860
Semi-finished product	7,566	8,618	2,763
Finished goods	134,260	142,550	179,614
Merchandise	11,830	-	-
	\$ 294,083	\$ 288,598	\$ 275,006

The components of the operating cost are as follows:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Cost of goods sold	\$ 470,413	\$ 458,917
Loss on inventory valuation and obsolescence	6,470	359
Inventory Write-off Loss	33	438
Income from sale of scraps and scraps	(2,169)	(2,036)
	\$ 474,747	\$ 457,678

X. Subsidiary

(I) Subsidiaries included in the consolidated financial statements

The entities in the consolidated financial statements are as follows:

Name of Investment Company	Name of subsidiary	Nature of business	Percentage of equity held			Description
			March 31, 2025	December 31, 2024	March 31, 2024	
The Company	Green Wealth Investments Limited (Green Wealth)	International investment	100	100	100	
The Company	Star Focus Inc. (Star Focus)	Medical device sales	40.67	100	-	Note 1
The Company	Optical Connection Technology Inc. (OCTI)	Medical device sales	98.36	-	-	Note 2
Green Wealth Investments Limited (Green Wealth)	Clear Precise Investments Limited (Clear Precise)	International investment	100	100	100	
Green Wealth Investments Limited (Green Wealth)	Vision Health Investments Limited (Vision Health)	International investment	100	100	-	Note 3
Clear Precise Investments Limited (Clear Precise)	Jiangsu Vizionfocus Inc.	R&D, design, and production of contact lens; wholesale and import and export of similar products of the above-mentioned products	80	80	80	

Note 1: In response to the company's overall operational development needs, the Company resolved at the Board of Directors meeting in November 2024 to establish a 100% owned subsidiary, Star Focus Inc., and completed the registration. In January 2025, the Company did not subscribe to Star Focus Inc.'s cash capital increase in proportion to its shareholding percentage, resulting in the shareholding percentage decreasing from 100% to 40.67%. As of March 31, 2025, the Company's management, after considering the absolute magnitude, relative size, and distribution of voting rights held compared to other shareholders, and given that all director positions of the subsidiary are held by the Company, determined that the Company possesses substantive ability to direct the relevant activities of Star Focus Inc., and therefore continues to classify it as a subsidiary.

Note 2: In response to the Company's overall operational development needs, the Company resolved through Board resolution in November 2024 to establish U.S. Subsidiary OCTI, and completed the remittance of investment funds in January 2025, holding a 98.36% ownership interest. This Company is primarily engaged in medical device sales.

Note 3: As of March 2025, the Company has not yet remitted investment funds and the subsidiary has no operational activities.

(II) Subsidiaries with significant non-controlling equity

Name of subsidiary	Shareholding and voting rights ratio held by non-controlling interests (%)		
	December 31,		
	March 31, 2025	2024	March 31, 2024
Jiangsu Vizionfocus Inc.	20	20	20

Please refer to Table 2 for information on principal places of business and countries of incorporation.

Name of subsidiary	Net income for the period distributed to non-controlling interests				
	January 1 to March 31, 2025	January 1 to March 31, 2024	Non-controlling interests		
	March 31, 2025	March 31, 2024	March 31, 2025	December 31, 2024	March 31, 2024
Jiangsu Vizionfocus Inc.	\$ 9,544	\$ 13,744	\$ 333,256	\$ 316,862	\$ 267,015

The summarized financial information of Jiangsu Vizionfocus Inc. is based on the amount before writing off the intercompany transactions:

	March 31, 2025	December 31, 2024	March 31, 2024
Current assets	\$ 809,503	\$ 760,006	\$ 656,920
Non-current assets	1,295,327	1,289,337	954,194
Current liabilities	(228,160)	(252,681)	(217,567)
Non-current liabilities	(210,388)	(212,352)	(58,474)
Equity	<u>\$ 1,666,282</u>	<u>\$ 1,584,310</u>	<u>\$ 1,335,073</u>

	March 31, 2025	December 31, 2024	March 31, 2024
Equity attributable to Owners of the Company	\$ 1,333,026	\$ 1,267,448	\$ 1,068,058
Non-controlling interests of Jiangsu Vizionfocus Inc.	<u>333,256</u>	<u>316,862</u>	<u>267,015</u>
	<u>\$ 1,666,282</u>	<u>\$ 1,584,310</u>	<u>\$ 1,335,073</u>

	January 1 to March 31, 2025	January 1 to March 31, 2024
Net operating revenue	<u>\$ 234,982</u>	<u>\$ 264,422</u>
Net income for the period	\$ 47,717	\$ 68,722
Other comprehensive income	-	-
Total comprehensive income	<u>\$ 47,717</u>	<u>\$ 68,722</u>

Net profit attributable to Owners of the Company	\$ 38,173	\$ 54,978
Non-controlling interests of Jiangsu Vizionfocus Inc.	<u>9,544</u>	<u>13,744</u>
	<u>\$ 47,717</u>	<u>\$ 68,722</u>

Total comprehensive income attributable to Owners of the Company	\$ 38,173	\$ 54,978
Non-controlling interests of Jiangsu Vizionfocus Inc.	<u>9,544</u>	<u>13,744</u>
	<u>\$ 47,717</u>	<u>\$ 68,722</u>

(To be Continued)

(Continued from previous page)

	January 1 to March 31, 2025	January 1 to March 31, 2024
Cash flow		
Operating activities	\$ 155,308	\$ 164,044
Investment activities	(118,962)	(68,637)
Financing activities	(4,523)	1,420
Effect of exchange rate changes	<u>12,710</u>	<u>8,722</u>
Net cash inflow	<u>\$ 44,533</u>	<u>\$ 105,549</u>

XI. Property, plant and equipment

January 1 to March 31, 2025

	Land	Machinery and equipment	Mold equipment	Transportation equipment	Office equipment	Leasehold improvements	Other equipment	Unfinished construction and equipment to be inspected	Total
<u>Cost</u>									
Balance on January 1, 2025	\$ 705,898	\$ 1,997,948	\$ 112,100	\$ 7,630	\$ 25,160	\$ 303,450	\$ 32,616	\$ 832,306	\$ 4,017,108
Addition	-	91,319	11,343	-	2,128	704	347	110,809	216,650
Disposition	-	(67)	-	-	-	-	(27)	-	(94)
Exchange difference, net	-	19,089	1,338	23	179	3,084	141	4,005	27,859
Balance on March 31, 2025	<u>705,898</u>	<u>2,108,289</u>	<u>124,781</u>	<u>7,653</u>	<u>27,467</u>	<u>307,238</u>	<u>33,077</u>	<u>947,120</u>	<u>4,261,523</u>
<u>Accumulated depreciation</u>									
Balance on January 1, 2025	-	781,222	68,618	6,020	18,763	132,117	14,894	-	1,021,634
Depreciation expense	-	63,649	5,472	230	1,062	8,892	2,077	-	81,382
Disposition	-	(67)	-	-	-	-	(27)	-	(94)
Exchange difference, net	-	4,400	571	23	119	1,160	50	-	6,323
Balance on March 31, 2025	-	<u>849,204</u>	<u>74,661</u>	<u>6,273</u>	<u>19,944</u>	<u>142,169</u>	<u>16,994</u>	-	<u>1,109,245</u>
Net as of December 31, 2024	<u>\$ 705,898</u>	<u>\$ 1,216,726</u>	<u>\$ 43,482</u>	<u>\$ 1,610</u>	<u>\$ 6,397</u>	<u>\$ 171,333</u>	<u>\$ 17,722</u>	<u>\$ 832,306</u>	<u>\$ 2,995,474</u>
Net as of March 31, 2025	<u>\$ 705,898</u>	<u>\$ 1,259,085</u>	<u>\$ 50,120</u>	<u>\$ 1,380</u>	<u>\$ 7,523</u>	<u>\$ 165,069</u>	<u>\$ 16,083</u>	<u>\$ 947,120</u>	<u>\$ 3,152,278</u>

January 1 to March 31, 2024

	Land	Machinery and equipment	Mold equipment	Transportation equipment	Office equipment	Leasehold improvements	Other equipment	Unfinished construction and equipment to be inspected	Total
<u>Cost</u>									
Balance on January 1, 2024	\$ 705,898	\$ 1,704,580	\$ 101,300	\$ 7,469	\$ 22,744	\$ 288,086	\$ 22,826	\$ 226,020	\$ 3,078,923
Addition	-	19,458	-	125	951	5,638	4,767	172,456	203,395
Exchange difference, net	-	13,242	919	19	133	2,573	93	2,362	19,341
Balance on March 31, 2024	<u>705,898</u>	<u>1,737,280</u>	<u>102,219</u>	<u>7,613</u>	<u>23,828</u>	<u>296,297</u>	<u>27,686</u>	<u>400,838</u>	<u>3,301,659</u>
<u>Accumulated depreciation</u>									
Balance on January 1, 2024	-	568,060	54,290	4,831	14,132	94,310	8,045	-	743,668
Depreciation expense	-	55,491	4,714	290	1,332	8,963	1,583	-	72,373
Exchange difference, net	-	2,331	298	15	68	639	24	-	3,375
Balance on March 31, 2024	-	<u>625,882</u>	<u>59,302</u>	<u>5,136</u>	<u>15,532</u>	<u>103,912</u>	<u>9,652</u>	-	<u>819,416</u>
<u>Accumulated impairment</u>									
Balance at January 1, 2024 and March 31, 2024	-	1,109	-	-	-	-	-	-	1,109
Net as of March 31, 2024	<u>\$ 705,898</u>	<u>\$ 1,110,289</u>	<u>\$ 42,917</u>	<u>\$ 2,477</u>	<u>\$ 8,296</u>	<u>\$ 192,385</u>	<u>\$ 18,034</u>	<u>\$ 400,838</u>	<u>\$ 2,481,134</u>

Property, plant and equipment are depreciated on a straight-line basis over the following useful lives:

Machinery and equipment	3 to 10 years
Mold equipment	2 to 5 years
Transportation equipment	4 to 5 years
Office equipment	3 to 7 years
Leasehold improvements	3 to 14 years
Other equipment	3 to 10 years

Please refer to Note 30 for the amount of property, plant and equipment pledged by the Company and its subsidiaries to secure borrowings.

XII. Lease agreement

(I) Right-of-use assets

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Book value of right-of-use assets			
Land	\$ 1,836	\$ 1,931	\$ 2,216
Buildings	352,107	351,464	196,659
Machinery and equipment	<u>284</u>	<u>325</u>	<u>447</u>
	<u>\$ 354,227</u>	<u>\$ 353,720</u>	<u>\$ 199,322</u>
	<u>January 1 to March 31, 2025</u>		<u>January 1 to March 31, 2024</u>
Addition of right-of-use assets	<u>\$ 13,912</u>		<u>\$ 8,334</u>
Depreciation expense of right-of-use assets			
Land	\$ 95		\$ 95
Buildings	12,698		7,688
Machinery and equipment	<u>41</u>		<u>41</u>
	<u>\$ 12,834</u>		<u>\$ 7,824</u>

Except for the additions and recognized depreciation mentioned above, the Company and its subsidiaries did not have any material subleases or impairment of right-of-use assets for the periods from January 1 to March 31, 2025 and 2024.

(II) Lease liabilities

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Book value of lease liabilities			
Current	<u>\$ 50,088</u>	<u>\$ 48,588</u>	<u>\$ 32,907</u>
Non-current	<u>\$ 310,819</u>	<u>\$ 311,051</u>	<u>\$ 175,696</u>

Discount rate interval (%) of lease liabilities is as follows:

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Land	1.605	1.605	1.605
Buildings	1.247~4.75	1.164~4.75	1.164~4.75
Machinery and equipment	1.023	1.023	1.023

(III) Important lease-in activities and terms and conditions

The Company and its subsidiaries leased offices, plants, machinery and equipment, and parking spaces, and the lease periods have gradually expired before the end of August 2034. Upon termination of the lease term, the Company and its subsidiaries have no preferential right to acquire the leased right-of-use assets, and it is agreed that the Company and its subsidiaries shall not sublease or transfer the subject of the lease, in whole or in part.

(IV) Other lease information

	January 1 to March 31, 2025	January 1 to March 31, 2024
Short-term and low-value lease expenses	<u>\$ 915</u>	<u>\$ 509</u>
Total cash outflows of all lease agreements (including short-term leases)	<u>\$ 15,481</u>	<u>\$ 9,153</u>

The Company and its subsidiaries have elected to apply the recognition exemption for leases of parking spaces and staff dormitories that qualify as short-term leases and other equipment that qualifies for low-value asset leases, and do not recognize right-of-use assets and lease liabilities for these leases.

XIII. Intangible assets

	March 31, 2025	December 31, 2024	March 31, 2024
Computer software	\$ 5,303	\$ 4,839	\$ 4,803
Product certificate	63,269	60,253	21,189
Intangible assets under development	46,125	47,584	54,984
Other intangible assets (primarily consisting of customer relationships, customer lists, and trademark rights)	<u>17,105</u>	<u>-</u>	<u>-</u>
	<u>\$ 131,802</u>	<u>\$ 112,676</u>	<u>\$ 80,976</u>

January 1 to March 31, 2025

	Computer software	Product certificate	Intangible assets under development	Other intangible assets	Total
<u>Cost</u>					
Balance on January 1, 2025	\$ 21,641	\$ 96,511	\$ 47,584	\$ -	\$ 165,736
Addition	1,499	-	3,096	17,218	21,813
Reclassification	-	4,961	(4,961)	-	-
Exchange difference, net	<u>130</u>	<u>848</u>	<u>406</u>	<u>163</u>	<u>1,547</u>
Balance on March 31, 2025	<u>23,270</u>	<u>102,320</u>	<u>46,125</u>	<u>17,381</u>	<u>189,096</u>
<u>Accumulated amortization</u>					
Balance on January 1, 2025	16,802	36,258	-	-	53,060
Amortization expense	1,057	2,379	-	273	3,709
Exchange difference, net	<u>108</u>	<u>414</u>	<u>-</u>	<u>3</u>	<u>525</u>
Balance on March 31, 2025	<u>17,967</u>	<u>39,051</u>	<u>-</u>	<u>276</u>	<u>57,294</u>
Net as of December 31, 2024	<u>\$ 4,839</u>	<u>\$ 60,253</u>	<u>\$ 47,584</u>	<u>\$ -</u>	<u>\$ 112,676</u>
Net as of March 31, 2025	<u>\$ 5,303</u>	<u>\$ 63,269</u>	<u>\$ 46,125</u>	<u>\$ 17,105</u>	<u>\$ 131,802</u>

January 1 to March 31, 2024

	Computer software	Product certificate	Intangible assets under development	Total
<u>Cost</u>				
Balance on January 1, 2024	\$ 16,880	\$ 48,822	\$ 52,851	\$ 118,553
Addition	426	-	3,018	3,444
Reclassification	-	885	(885)	-
Exchange difference, net	<u>95</u>	<u>423</u>	<u>-</u>	<u>518</u>
Balance on March 31, 2024	<u>17,401</u>	<u>50,130</u>	<u>54,984</u>	<u>122,515</u>
<u>Accumulated amortization</u>				
Balance on January 1, 2024	11,037	26,813	-	37,850
Amortization expense	1,479	1,896	-	3,375
Exchange difference, net	<u>82</u>	<u>232</u>	<u>-</u>	<u>314</u>
Balance on March 31, 2024	<u>12,598</u>	<u>28,941</u>	<u>-</u>	<u>41,539</u>
Net as of March 31, 2024	<u>\$ 4,803</u>	<u>\$ 21,189</u>	<u>\$ 54,984</u>	<u>\$ 80,976</u>

The above-mentioned intangible assets with finite useful lives are amortized on a straight-line basis based on the following useful lives:

Computer software	1 to 5 years
Product certificate	5 to 10 years
Other intangible assets	15 years

The amount prepaid by the Company and its subsidiaries to apply for the relevant product certificate are recognized as intangible assets under development and will be transferred to intangible assets - product certificate when the approval certificate is duly obtained.

XIV. Long-term borrowings

	March 31, 2025	December 31, 2024	March 31, 2024
Credit loans			
Expiring successively before November 2029	\$ 527,742	\$ 988,105	\$ 1,114,684
Secured borrowings			
Expiring successively by March 2035	<u>521,700</u>	<u>-</u>	<u>39,157</u>
	1,049,442	988,105	1,153,841
Less: Due within one year	155,279	156,078	186,601
Less: Recognized as deferred income – current (Note 24)	4,017	4,107	6,080
Less: Recognized as deferred income – non-current (Note 24)	<u>9,102</u>	<u>8,463</u>	<u>11,522</u>
	<u>\$ 881,044</u>	<u>\$ 819,457</u>	<u>\$ 949,638</u>
		December 31,	
	March 31, 2025	2024	March 31, 2024
Interest rate range (%)			
Credit loans	0.725~0.825	0.725~1.82	0.725~3.95
Secured borrowings	1.62~1.82	-	0.725

According to the loan agreements signed between the Company and Mega Bank, Chinatrust Bank and Taishin Bank, the relevant financial ratios and amounts of the semi-annual consolidated financial statements audited and certified by the CPA for the Company and its subsidiaries should comply with certain ratios. The aforementioned regulations are subject to review once every six months or annually, and the Company's consolidated financial statements for 2024 did not violate the aforementioned regulations.

Please refer to Notes 29 and 30 for the status of joint guarantees and collateral provided for long-term borrowings by the Company and its subsidiaries.

XV. Accounts payable

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Accounts payable	\$ 197,550	\$ 194,453	\$ 182,185

The Company and its subsidiaries have financial risk management policies to ensure that all payables are repaid within the pre-agreed credit terms.

XVI. Other payables

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Remuneration payable to employees and directors	\$ 117,789	\$ 90,270	\$ 131,291
Payables for equipment	56,948	43,745	54,156
Payable insurance premiums and pensions	48,945	48,693	38,694
Salary payable	41,749	39,454	39,116
Bonus payable	26,412	66,658	20,643
Others (consumables, repairs, and miscellaneous purchases)	<u>51,872</u>	<u>47,332</u>	<u>55,676</u>
	<u>\$ 343,715</u>	<u>\$ 336,152</u>	<u>\$ 339,576</u>

XVII. Post-employment benefit plan

The Company's pension system under the "Labor Pension Act" is a state-managed defined contribution plan. Under the Labor Pension Act, the Company makes monthly contributions to employees' individual pension accounts at 6% of their monthly salaries and wages.

According to the local laws and regulations, the subsidiaries in Mainland China are required to contribute a specific percentage of the salary cost to the relevant government departments.

The defined benefit plan-related pension expenses recognized for the periods from January 1 to March 31, 2025 and 2024 were calculated using pension cost rates actuarially determined as of December 31, 2024 and 2023, amounting to NT\$373 thousand and NT\$397 thousand, respectively.

XVIII. Equity

(I) Common stock capital

	March 31, 2025	December 31, 2024	March 31, 2024
Rated number of shares (thousand shares)	<u>80,000</u>	<u>80,000</u>	<u>80,000</u>
Authorized share capital	<u>\$ 800,000</u>	<u>\$ 800,000</u>	<u>\$ 800,000</u>
Number of issued and fully paid shares (thousand shares)	<u>58,045</u>	<u>57,925</u>	<u>57,512</u>
Issued share capital	<u>\$ 580,447</u>	<u>\$ 579,247</u>	<u>\$ 575,117</u>

On December 13, 2023, the Board of Directors resolved to issue 5,057 thousand new shares with a par value of NT\$10 per share for cash capital increase. The capital increase was approved by the Securities and Futures Bureau of the Financial Supervisory Commission on January 10, 2024. The Board of Directors designated March 14, 2024 as the base date for the capital increase, and the change in capital was completed and registered on April 15, 2024.

The aforementioned cash capital increase included a public offering, competitive auction, and employee subscription. The public offering and employee subscription were issued at a premium of NT\$180 per share, while the competitive auction was issued at a premium of NT\$260.51 per share, which was the weighted average of the winning bid price. The total issuance amount of NT\$1,195,263 thousand was fully received, and after deducting issuance costs of NT\$3,000 thousand, NT\$50,570 thousand was recorded as ordinary share capital and NT\$1,141,693 thousand as capital surplus – share premium. Regarding the recognition of compensation costs related to the new shares reserved for employee subscription from the cash capital increase, please refer to Note 23.

From January 1 to March 31, 2025, the Company issued 120 thousand shares due to employees exercising stock options at a weighted average price of NT\$114.41 per share issued at premium. The difference between issue price and par value of NT\$12,529 thousand was recorded under capital surplus - premium on stock issuance. Of these shares, the Company plans to register 30 thousand shares with the Ministry of Economic Affairs after the approval and issuance of this financial report.

In 2024, the Company issued 413 thousand shares due to employees exercising stock options, issued at a premium of NT\$28.96 per share. The difference between the issuance price and par value of NT\$7,831 thousand was recorded under capital surplus - additional paid-in capital from share issuance.

(II) Capital reserve

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Can be used to offset losses, distribute cash or capitalize on share capital (Note 1)			
Premium from stock issuance	\$ 1,829,914	\$ 1,814,601	\$ 1,802,917
Difference Between the Fair Value and Carrying Amount of the Consideration Paid or Received for the Acquisition or Disposal of Subsidiaries	29	-	-
From gifts and acceptances (Note 2)	1,800	1,800	1,800
<u>Not to be used for any purpose</u>			
Employee share warrants	<u>9,590</u>	<u>11,694</u>	<u>12,251</u>
	<u>\$ 1,841,333</u>	<u>\$ 1,828,095</u>	<u>\$ 1,816,968</u>

Note 1: Such capital reserves may be used to make up for deficits, and may be used to distribute cash or capitalize on share capital when the Company has no losses. However, the capital reserves shall be limited to a certain percentage of the paid-in capital each year.

Note 2: Assets donated by the Company as received by the Chairman.

(III) Retained earnings and dividend policy

According to the Company's Articles of Incorporation, if there is a profit at the end of the year, it shall first pay taxes and make up for past losses and then distribute it as follows:

1. Set aside 10% as a legal reserve, unless the legal reserve reaches the amount of the Company's paid-in capital.
2. Provision or reversal of special reserve in accordance with the regulations of the competent authority.
3. The remainder is added to the accumulated undistributed earnings of the previous years as the earnings available for distribution, and the board of directors prepares an earnings appropriation proposal and submits it to the shareholders' meeting for resolution.

The Company pursues sustainable operations and stable management and development in line with the overall environment, industry growth characteristics, and the Company's long-term financial planning. The Company adopts a residual dividend policy where the annual fund needs are measured based on the Company's future capital budget planning. After the funds required for financing are reserved, the remaining earnings may be distributed in the form of cash dividends and stock dividends. The distribution steps are as follows:

1. Determine the optimal capital budget.
2. Determine the funds required for financing for the aforesaid capital budget.
3. Determine how much of the funds for financing are covered by retained earnings.
4. After an appropriate portion of the remaining earnings is retained depending on the operational needs, the remainder may be distributed to shareholders in the form of dividends. The amount to be distributed

shall not be less than 10% of the Company's distributable earnings for the year, provided that the cash dividend shall not be less than 10% of the total dividends to be distributed.

The legal reserve can be used to make up for losses. When the company has no losses, the portion of the legal reserve exceeding 25% of the total paid-in capital can be allocated to capital and distributed in cash.

The Company's Board of Directors in March 2025 and shareholders' meeting in May 2024 proposed and resolved, respectively, the following appropriations of 2024 and 2023 earnings and cash dividends per share:

	Proposal for the distribution		Dividends per share (NTD)	
	of earnings		2024	2023
	2024	2023	2024	2023
Statutory Reserve	\$ 66,942	\$ 27,149		
Appropriation (reversal) of special reserve	(9,499)	9,499		
Cash dividends	322,641	187,263	\$ 5.57	\$ 3.23

The proposal for 2024 earnings distribution is pending resolution at the Annual Shareholders' Meeting expected to be held in May 2025.

(IV) Other equity

Exchange differences on translation of financial statements of foreign operations:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Opening balance	\$ 19,275	\$ (9,499)
Exchange differences arising from the translation of net assets of foreign operations	27,620	19,135
Related income tax	(5,524)	(3,827)
Closing balance	<u>\$ 41,371</u>	<u>\$ 5,809</u>

(V) Non-controlling interests

	January 1 to March 31, 2025	January 1 to March 31, 2024
Opening balance	\$ 316,862	\$ 248,487
Net income for the period	8,585	13,744
Other comprehensive income in the current period		
Foreign Currency Translation Adjustment	6,859	4,784
Changes in non-controlling interests due to subsidiary capital increase (Note 25)	35,571	-
Increase in non-controlling interests from acquisition of subsidiaries	820	-
Closing balance	<u>\$ 368,697</u>	<u>\$ 267,015</u>

XIX. Revenue

	January 1 to March 31, 2025	January 1 to March 31, 2024
Revenue from contracts with customers		
Merchandise sales revenue	\$ 808,132	\$ 766,280
Others	2,403	1,753
	<u>\$ 810,535</u>	<u>\$ 768,033</u>

(I) Contract balance

	March 31, 2025	December 31, 2024	March 31, 2024	January 1, 2024
Notes and accounts receivable	<u>\$ 650,872</u>	<u>\$ 641,421</u>	<u>\$ 570,123</u>	<u>\$ 621,171</u>
Contract liabilities				
Sales of goods	<u>\$ 7,931</u>	<u>\$ 4,384</u>	<u>\$ 4,691</u>	<u>\$ 6,279</u>

The changes in contract liabilities were primarily due to timing differences between satisfying performance obligations and customer payments for the periods from January 1 to March 31, 2025 and 2024, with no other significant changes.

The amounts of revenue recognized in the current period that were included in the opening contract liability balance:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Contract liabilities at the beginning of the year		
Sales of goods	<u>\$ 4,381</u>	<u>\$ 6,279</u>

(II) Breakdown of revenue from customer contracts
January 1 to March 31, 2025

	Reporting department		
	Contact lens - injection molded sheet	Others	Total
Type of income			
Merchandise sales revenue	\$ 808,132	\$ -	\$ 808,132
Other operating revenue	<u>-</u>	<u>2,403</u>	<u>2,403</u>
	<u>\$ 808,132</u>	<u>\$ 2,403</u>	<u>\$ 810,535</u>

January 1 to March 31, 2024

	Reporting department		
	Contact lens - injection molded sheet	Others	Total
Type of income			
Merchandise sales revenue	\$ 766,280	\$ -	\$ 766,280
Other operating revenue	<u>-</u>	<u>1,753</u>	<u>1,753</u>
	<u>\$ 766,280</u>	<u>\$ 1,753</u>	<u>\$ 768,033</u>

XX. Net income before tax

Net income before tax includes the following items:

(I) Interest revenue

	January 1 to March 31, 2025	January 1 to March 31, 2024
Bank deposits	\$ 3,450	\$ 3,526
Others	<u>14</u>	<u>13</u>
	<u>\$ 3,464</u>	<u>\$ 3,539</u>

(II) Other income	January 1 to March 31, 2025	January 1 to March 31, 2024
Government grant income	\$ 9,130	\$ 1,838
Others	<u>1,061</u>	<u>2,649</u>
	<u>\$ 10,191</u>	<u>\$ 4,487</u>

(III) Other gains and losses	January 1 to March 31, 2025	January 1 to March 31, 2024
Net gain from foreign currency exchange	\$ 10,761	\$ 13,606
Gains from the disposal of property, plant and equipment	25	-
Others	<u>23</u>	<u>(60)</u>
	<u>\$ 10,809</u>	<u>\$ 13,546</u>

The above net foreign currency exchange gains and losses are detailed as follows:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Total foreign exchange gains	\$ 11,815	\$ 17,276
Total foreign currency exchange losses	<u>(1,054)</u>	<u>(3,670)</u>
Net profit	<u>\$ 10,761</u>	<u>\$ 13,606</u>

(IV) Finance Costs	January 1 to March 31, 2025	January 1 to March 31, 2024
Interest on bank borrowings	\$ 4,114	\$ 6,392
Interest on lease liabilities	<u>2,561</u>	<u>938</u>
	<u>\$ 6,675</u>	<u>\$ 7,330</u>

(V) Depreciation and amortization	January 1 to March 31, 2025	January 1 to March 31, 2024
Property, plant and equipment	\$ 81,382	\$ 72,373
Right-of-use assets	12,834	7,824
Intangible assets	<u>3,709</u>	<u>3,375</u>
	<u>\$ 97,925</u>	<u>\$ 83,572</u>
Depreciation expenses by function		
Operating cost	\$ 89,892	\$ 77,013
Operating expenses	<u>4,324</u>	<u>3,184</u>
	<u>\$ 94,216</u>	<u>\$ 80,197</u>
Amortization expenses by function		
Operating cost	\$ 931	\$ 1,348
Operating expenses	<u>2,778</u>	<u>2,027</u>
	<u>\$ 3,709</u>	<u>\$ 3,375</u>

(VI) Employee benefit expense

	January 1 to March 31, 2025	January 1 to March 31, 2024
Short-term employee benefits		
Salary	\$ 165,430	\$ 171,191
Labor and national health insurance	13,536	11,473
Others	<u>11,420</u>	<u>12,364</u>
	190,386	195,028
Post-employment benefits		
Defined contribution plan	3,368	7,560
Defined benefit plan (Note 17)	<u>373</u>	<u>397</u>
	<u>\$ 194,127</u>	<u>\$ 202,985</u>
Summary by function		
Operating cost	\$ 131,597	\$ 143,674
Operating expenses	<u>62,530</u>	<u>59,311</u>
	<u>\$ 194,127</u>	<u>\$ 202,985</u>

(VII) Remuneration to employees and directors

The company allocates employee and director remunerations based on pre-tax net income before distributions to employees and directors at rates ranging from 1% to 12% and up to 1.5%, respectively. However, if the company still has accumulated losses, it must first reserve amounts to cover these losses before allocating employee and director remunerations according to the aforementioned percentages.

Following amendments to the Securities and Exchange Act in August 2024, the Company expects to resolve at the 2025 shareholders' meeting to amend its articles of incorporation, stipulating that from the amount allocated for employee compensation, no less than 1% shall be allocated as compensation distributed to entry-level employees.

For the periods from January 1 to March 31, 2025 and 2024, the estimated amounts of employee compensation and directors' remuneration are as follows:

Amount	January 1 to March 31, 2025	January 1 to March 31, 2024
Remuneration to employees	\$ 22,735	\$ 22,571
Remuneration to directors	1,765	2,058

If there is still a change in the amount of the annual consolidated financial statements after the publication date, it will be treated as a change in the accounting estimate and will be adjusted and accounted for in the following year.

In March 2025 and 2024, the Company's Board of Directors approved the following amounts of employee compensation and directors' remuneration for 2024 and 2023, respectively:

Amount	2024	2023
Remuneration to employees	\$ 54,688	\$ 77,704
Remuneration to directors	5,633	8,547

There is no difference between the actual amount of employees' and directors' remuneration distributed for 2024 and 2023 and the amount recognized in the consolidated financial statements.

For information on employees' remuneration and remuneration of directors resolved by the Company's board of directors, please visit the Market Observation Post System of the Taiwan Stock Exchange.

XXI. Income tax

(I) Income tax recognized in profit or loss

The main components of income tax expense are as follows:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Current income tax		
Incurred in the current period	\$ 49,911	\$ 33,822
Deferred income tax		
Incurred in the current period	<u>5,045</u>	<u>22,962</u>
	<u>\$ 54,956</u>	<u>\$ 56,784</u>

(II) Income tax recognized in other comprehensive income

	January 1 to March 31, 2025	January 1 to March 31, 2024
Deferred income tax		
Foreign Currency Translation Adjustment	<u>\$ 5,524</u>	<u>\$ 3,827</u>

(III) Authorization of income tax

The income tax returns of the Company up to 2023 have been approved by the tax authorities.

XXII. Earnings per share

The net income and the weighted average number of ordinary shares used to calculate the earnings per share are as follows:

Net income for the period

	January 1 to March 31, 2025	January 1 to March 31, 2024
Net income attributable to owners of the Company	<u>\$ 192,731</u>	<u>\$ 182,829</u>

Number of shares (unit: thousand)

	January 1 to March 31, 2025	January 1 to March 31, 2024
Weighted average number of ordinary shares for calculation of basic earnings per share	58,004	53,399
Potential dilutive ordinary shares		
Employee share warrants	589	1,121
Remuneration to employees	<u>332</u>	<u>265</u>
Weighted average number of ordinary shares for calculation of diluted earnings per share	<u>58,925</u>	<u>54,785</u>

If the company chooses to distribute employee remunerations in either stock or cash, when calculating diluted earnings per share, it is assumed that remunerations will be paid in stock, and this potential common stock is included in the weighted average number of shares outstanding when it has a dilutive effect to compute diluted earnings per share. The dilutive effect of these potential ordinary shares will also be taken into account when calculating the diluted earnings per share before the number of shares to be distributed to employees in the following year.

XXIII. Share-based payment agreement

(I) Initial public offering and underwriting

On December 13, 2023, the Company's Board of Directors resolved to conduct an initial public offering by issuing new shares for cash capital increase and reserved 632 thousand shares for employee subscription in accordance with the Company Act. If any shares reserved for employee subscription remain unsubscribed or are waived, the chairman is authorized to seek subscription from specific individuals. On the grant date, the Company recognized compensation costs and capital surplus – employee share options of NT\$20,403 thousand based on an option pricing model.

The Company's employees and specific individuals subscribed for 632 thousand ordinary shares at an exercise price of NT\$180 per share. The Company transferred NT\$20,403 thousand from capital surplus – employee share options to capital surplus – share premium (from share options exercised).

(II) Employee stock option plan

In May 2021 and December 2022, the company's board of directors resolved to issue 1,700 thousand and 300 thousand stock options to employees, respectively. Each unit entitles the holder to subscribe for one ordinary share and is available to employees who meet specific eligibility criteria. The warrants have a lifespan of six years. The holders can exercise a certain proportion of their subscription rights starting two years after the issue date. Following the issuance of the warrants, if there are any changes in the issuance of the company's ordinary shares, the exercise price of the warrants will be adjusted according to the specified formula.

Information on employee stock options is as follows:

	<u>January 1 to March 31, 2025</u>		<u>January 1 to March 31, 2024</u>	
	<u>Unit</u>	<u>Weighted</u>	<u>Unit</u>	<u>Weighted</u>
	<u>(Thousands)</u>	<u>average</u>	<u>(Thousands)</u>	<u>average</u>
		<u>exercise price</u>		<u>exercise price</u>
		<u>(NTD)</u>		<u>(NTD)</u>
<u>Employee share warrants</u>				
Shares outstanding at beginning of period	906		1,343	
Forfeitures during the period	-		(20)	
Grants during the period	<u>(120)</u>	<u>\$ 114.41</u>	<u>-</u>	<u>\$ -</u>
Shares outstanding at end of period	<u>786</u>	<u>\$ 49.12</u>	<u>1,323</u>	<u>\$ 48.98</u>
Executable at the end of period	<u>54</u>		<u>-</u>	

As of March 31, 2025, information on outstanding employee stock options is as follows:

<u>Range of exercise price</u>	<u>Weighted average remaining contract term (years)</u>
\$28.96~122.18	2.88

The Company adopts the Black-Scholes valuation model for granting stock warrants to employees, and the inputs used in the valuation model are as follows:

	<u>2022</u>	<u>2021</u>
Grant-date stock price	NT\$99.72	NT\$29.26
Exercise price	NT\$129.4	NT\$30
Expected stock price volatility (%)	40.68~41.53	39.03~39.64
Expected duration (year)	4~4.5	4~5
Expected dividend yield	-	-
Expected subscription ratio (%)	100	100
Risk-free interest rate (%)	1.12~1.13	0.26~0.28

For the periods from January 1 to March 31, 2025 and 2024, the Company recognized compensation costs of NT\$680 thousand and NT\$1,198 thousand, respectively, with corresponding amounts recognized in capital surplus – employee share options.

From January 1 to March 31, 2025, the Company transferred NT\$2,784 thousand from capital surplus – employee stock options to capital surplus – additional paid-in capital due to the exercise of employee stock options.

XXIV. Government grants

The company has obtained government-subsidized loans with preferential interest rates under the ‘Welcoming Taiwanese Businesses to Invest Back in Taiwan Action Plan’, which are used for capital expenditures and working capital needs. The fair value of these loans is estimated based on the interest rates under normal conditions of the company. The difference between the fair value and the amount of the loans obtained is considered a government subsidy for low-interest loans and is recognized as deferred income:

	<u>January 1 to March 31, 2025</u>	<u>January 1 to March 31, 2024</u>
Opening balance	\$ 12,570	\$ 16,384
Recognition of difference in fair value in current period	1,599	3,041
Recognized in current period (accounted for other income)	<u>(1,050)</u>	<u>(1,823)</u>
Closing balance	<u>\$ 13,119</u>	<u>\$ 17,602</u>

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
<u>Book value of deferred income</u>			
Deferred revenue	\$ 4,017	\$ 4,107	\$ 6,080
Long-term deferred revenue	<u>9,102</u>	<u>8,463</u>	<u>11,522</u>
	<u>\$ 13,119</u>	<u>\$ 12,570</u>	<u>\$ 17,602</u>

XXV. Equity transactions with non-controlling interests - January 1 to March 31, 2025 only

In January 2025, the Company did not subscribe to subsidiary Star Focus Inc.’s cash capital increase in proportion to its shareholding, resulting in the shareholding percentage decreasing from 100% to 40.67%. Since the above transaction did not

change the Company's control over the subsidiary, the Company treated it as an equity transaction. Related information is as follows:

	January 1 to March 31, 2025
Cash consideration received	\$ 35,600
Amount of subsidiary's net asset carrying value to be transferred to non-controlling interests calculated based on relative change in equity interest	<u>(35,571)</u>
Equity transaction balance	<u>\$ 29</u>

The Company's adjustment to the above equity transaction difference is as follows:

	January 1 to March 31, 2025
Capital reserve - the difference between the price of the subsidiary's equity actually acquired or disposed of and the book value	<u>\$ 29</u>

XXVI. Non-cash transactions

For the periods from January 1 to March 31, 2025 and 2024, the Company and subsidiaries had the following non-cash investing activities:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Investment activities that affect both cash and non-cash items		
Increase in property, plant and equipment	\$ 216,650	\$ 203,395
Increase of payables for equipment	(13,203)	(739)
Prepaid equipment purchase increase (decrease)	<u>7,235</u>	<u>(4,525)</u>
Amount of cash paid	<u>\$ 210,682</u>	<u>\$ 198,131</u>

XXVII. Capital risk management

The Company and its subsidiaries manage capital to ensure that they can optimize the balance of debt and equity to ensure the efficient use of capital and the smooth operation of the Company and subsidiaries under the premise of continuing to operate.

The company and its subsidiaries' capital structure consists of net debt and equity. The senior management regularly reviews the capital structure based on the current industry operational status and future development of the company, considering factors such as changes in the external environment. The review includes the cost of various types of capital and related risks, balancing the overall capital structure through issuing new shares, procuring new debt, and repaying existing debts.

XXVIII. Financial instruments

(I) Information on fair value - financial instruments not measured at fair value

The Company and its subsidiaries' management believe that the carrying amounts of financial assets and financial liabilities not measured at fair value approximate their fair values.

(II) Type of financial instruments

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Financial assets</u>			
Measured at amortized cost (Note 1)	\$ 2,297,981	\$ 2,089,471	\$ 2,377,968
<u>Financial liabilities</u>			
Measured at amortized cost (Note 2)	1,577,830	1,506,585	1,660,611

Note 1: The balance includes financial assets measured at amortized cost such as cash and cash equivalents, notes and accounts receivable, other receivables, other financial assets – current, and refundable deposits.

Note 2: The balance includes accounts payable, other payables, refund liabilities (classified under other current liabilities), long-term borrowings (including long-term borrowings due within one year), and refundable deposits (classified under other non-current liabilities) , as well as financial liabilities measured at amortized cost.

(III) Financial risk management objectives and policies

The main financial instruments of the Company and its subsidiaries include accounts receivable, long-term and short-term loans, accounts payable and lease liabilities. The financial management department provides services for each business unit and coordinates the operation of entering the domestic financial market. Extensive analysis of risk exposure and internal risk reports; monitoring and management of financial risks related to the operations of the Company and its subsidiaries. Such risks include market risk (including exchange rate risk and interest rate risk), credit risk and liquidity risk.

1. Market risk

The main financial risks to which the Company and its subsidiaries are exposed are the risk of changes in foreign currency exchange rates (see (1) below) and the risk of changes in interest rates (see (2) below).

There has been no change to the Company's and subsidiaries' exposure to market risks of financial instruments and the management and measurement of such exposures.

(1) Exchange rate risk

The Company and its subsidiaries engage in activities such as sales and purchase transactions, capital expenditures, and equity investments that are denominated in non-functional currencies, resulting in exchange rate risk. To the extent permitted by the policies, the Company and its subsidiaries utilize the purchase of foreign currency deposits and the claims and liabilities in the same category of foreign currency generated from the transactions to manage and reduce risks.

For the carrying amounts of monetary assets and monetary liabilities denominated in non-functional currencies of the Company and its subsidiaries at the balance sheet date, please refer to Note 32.

The Company and its subsidiaries were mainly affected by fluctuations in the exchange rates of the USD and CNY. The following table details a sensitivity analysis when the functional currency of the company depreciates by 1% against the US dollar and the Chinese Yuan. The 1% sensitivity ratio is used internally by the company to report

exchange rate risks to senior management and represents management's assessment of the reasonably possible range of foreign exchange rate fluctuations. The sensitivity analysis only includes monetary items in USD and RMB outstanding.

	January 1 to March 31, 2025	January 1 to March 31, 2024
<u>Impact of USD</u>		
Net income before tax	\$ 3,029	\$ 1,650
<u>Impact of RMB</u>		
Net income before tax	1,654	2,325

Note : It is mainly derived from the outstanding USD and RMB (including cash and cash equivalents, accounts receivable and borrowings) that are still outstanding at the end of the reporting period as cash flow hedges.

Management believes that sensitivity analysis cannot represent the inherent risk of exchange rates, as the foreign currency exposure at the balance sheet date does not reflect exposures during the period, and sales denominated in USD and RMB may vary with customer orders and economic cycles.

(2) Interest rate risk

As the Company and its subsidiaries borrow funds at floating interest rates, interest rate risk exposure arises. The Company and its subsidiaries manage the interest rate risk by maintaining an appropriate portfolio of floating interest rates.

The carrying amounts of financial assets and financial liabilities of the Company and its subsidiaries with exposure to the interest rate risk on the balance sheet date are as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Fair value interest rate risk			
Financial assets	\$ 839,532	\$ 643,078	\$ 846,612
Financial liabilities	360,907	359,639	208,603
Cash flow interest rate risk			
Financial assets	780,779	787,657	946,481
Financial liabilities	1,036,323	975,535	1,136,239

The following sensitivity analysis is based on the interest rate risk exposure of the non-derivative instruments at the balance sheet date. For liabilities with floating interest rates, the analysis method is based on the assumption that the amount of liabilities outstanding on the balance sheet date is outstanding throughout the reporting period. The rate of change used by the Company and subsidiaries to report interest rates to management is increased or decreased by 1%, which also represents management's assessment of the reasonably possible range of interest rates.

If interest rates on financial liabilities increased by 1%, with all other variables held constant, the Company's pre-tax net income for the periods from January 1 to March 31, 2025 and 2024 would have decreased by NT\$2,591 thousand and NT\$2,841 thousand, respectively.

2. Credit risk

Credit risk refers to the risk of financial loss to the Company and its subsidiaries due to the counterparty's default on contractual obligations. As of the balance sheet date, the maximum credit risk exposure of the Company and its subsidiaries that may cause financial losses due to the counterparty's failure to perform its obligations is the book value of financial assets recognized in the balance sheet.

All of the company and its subsidiaries' trading partners are companies with good creditworthiness. Business units grant trading credit limits based on the results of each credit assessment, and they regularly track the collection of receivables. In recent years, there have been very few actual cases of bad debts, and thus no significant credit risks are anticipated.

The company and its subsidiaries' receivables are significantly concentrated with several clients who engage in similar commercial activities and have similar economic characteristics. Consequently, their ability to fulfill contractual obligations is similarly affected by economic or other conditions, leading to a significant concentration of credit risk. The net accounts receivable of customers with significant concentration of credit risk are as follows:

Customer name	December 31,		
	March 31, 2025	2024	March 31, 2024
Company A	\$ 169,949	\$ 175,156	\$ 177,306
Company B	103,705	26,147	563
Company C	27,833	99,680	60,444
Company D	19,231	53,685	72,572

3. Liquidity risk

The Company and its subsidiaries manage and maintain sufficient cash position to support the Company's operations and mitigate the impact of cash flow fluctuations. They also monitor the use of bank financing facilities and ensure compliance with the terms of the loan contract.

Bank borrowings are an important source of liquidity for the Company and its subsidiaries. As of March 31, 2025, December 31, 2024, and March 31, 2024, the Company and its subsidiaries had unutilized bank loan facilities of NT\$4,851,734 thousand, NT\$3,860,126 thousand, and NT\$2,073,523 thousand, respectively. Therefore, there was no liquidity risk arising from the inability to raise funds to fulfill contractual obligations.

The following table shows the non-derivative financial liabilities of the Company and its subsidiaries. The analysis is based on the remaining contractual maturity of the agreed repayment period, and is prepared based on the undiscounted cash flow of the earliest possible date on which repayment may be required (including interest and principal cash flows).

The bank borrowings that the Company and its subsidiaries may be required to repay immediately are serialized within the earliest period in the following table, regardless of the possibility of the bank executing the right immediately. The maturity analysis of other non-derivative financial liabilities is based on the agreed repayment date preparation.

March 31, 2025

	<u>Within 1 year</u>	<u>1 to 5 years</u>	<u>More than 5 years</u>	<u>Total</u>
Non-interest-bearing liabilities	\$ 541,265	\$ 242	\$ -	\$ 541,507
Instruments with floating interest rates	166,582	841,833	76,728	1,085,143
Lease liabilities	<u>59,776</u>	<u>199,518</u>	<u>148,361</u>	<u>407,655</u>
	<u>\$ 767,623</u>	<u>\$ 1,041,593</u>	<u>\$ 225,089</u>	<u>\$ 2,034,305</u>

Further information on the maturity analysis of lease liabilities is as follows:

	<u>Less than 1 year</u>	<u>1 to 5 years</u>	<u>5 to 10 years</u>	<u>10 to 15 years</u>
Lease liabilities	\$ 59,776	\$ 199,518	\$ 148,361	\$ -

December 31, 2024

	<u>Within 1 year</u>	<u>1 to 5 years</u>	<u>More than 5 years</u>	<u>Total</u>
Non-interest-bearing liabilities	\$ 530,605	\$ 237	\$ -	\$ 530,842
Instruments with floating interest rates	165,921	847,665	-	1,013,586
Lease liabilities	<u>58,301</u>	<u>194,765</u>	<u>154,746</u>	<u>407,812</u>
	<u>\$ 754,827</u>	<u>\$ 1,042,667</u>	<u>\$ 154,746</u>	<u>\$ 1,952,240</u>

Further information on the maturity analysis of lease liabilities is as follows:

	<u>Less than 1 year</u>	<u>1 to 5 years</u>	<u>5 to 10 years</u>	<u>10 to 15 years</u>
Lease liabilities	\$ 58,301	\$ 194,765	\$ 154,746	\$ -

March 31, 2024

	<u>Within 1 year</u>	<u>1 to 5 years</u>	<u>More than 5 years</u>	<u>Total</u>
Non-interest-bearing liabilities	\$ 521,761	\$ 234	\$ -	\$ 521,995
Instruments with floating interest rates	198,496	951,347	35,461	1,185,304
Lease liabilities	<u>36,373</u>	<u>120,133</u>	<u>66,361</u>	<u>222,867</u>
	<u>\$ 756,630</u>	<u>\$ 1,071,714</u>	<u>\$ 101,822</u>	<u>\$ 1,930,166</u>

Further information on the maturity analysis of lease liabilities is as follows:

	<u>Less than 1 year</u>	<u>1 to 5 years</u>	<u>5 to 10 years</u>	<u>10 to 15 years</u>
Lease liabilities	\$ 36,373	\$ 120,133	\$ 62,031	\$ 4,330

XXIX. Related party transactions

(I) Names of related parties and their relationships

<u>Name of related party</u>	<u>Relationship with the Company and its subsidiaries</u>
An Shih Chang Wah Electromaterials Inc.	Key management personnel of the Company Serving as the Company's institutional director
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd (Jiangsu Yuyue)	Substantive related party
Jiangsu No.1 Garden Investment Co., Ltd.	Substantive related party
Jiangsu Joyea Co., Ltd. (Jiangsu Joyea)	Substantive related party

(II) Closing balance

<u>Presentation account</u>	<u>Category/Name of related party</u>	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Prepayment for equipment	Jiangsu Joyea	<u>\$ 19,020</u>	<u>\$ 18,625</u>	<u>\$ 4,326</u>
Refundable deposits	Jiangsu Yuyue	<u>\$ 7,134</u>	<u>\$ 6,986</u>	<u>\$ 1,102</u>
Other payables	Substantive related party	<u>\$ 1,795</u>	<u>\$ 448</u>	<u>\$ 2,369</u>

(III) Acquisition of property, plant and equipment

<u>Name of related party</u>	<u>January 1 to March 31, 2025</u>	<u>January 1 to March 31, 2024</u>
Proceeds from acquisition Jiangsu Joyea	<u>\$ 6,323</u>	<u>\$ -</u>

The Company and its subsidiaries have not purchased similar property, plant and equipment from non-related parties, so the transaction prices cannot be compared, and there is no significant difference in payment terms compared to general manufacturers.

(IV) Lease agreement

<u>Presentation account</u>	<u>Name of related party</u>	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Lease liabilities (including current and non-current)	Jiangsu Yuyue	<u>\$ 190,355</u>	<u>\$ 190,889</u>	<u>\$ 19,473</u>

<u>Category/Name of related party</u>	<u>January 1 to March 31, 2025</u>	<u>January 1 to March 31, 2024</u>
Interest expense Jiangsu Yuyue	<u>\$ 1,934</u>	<u>\$ 238</u>

The subsidiary has leased a plant from Jiangsu Yuyue since October 2019. The lease period expires in December 2034. The rent is calculated based on the floor area (in square feet) and fixed lease payments are paid on a quarterly basis in accordance with the lease contract.

(V) Remuneration of key management personnel

	<u>January 1 to March 31, 2025</u>	<u>January 1 to March 31, 2024</u>
Short-term employee benefits	<u>\$ 15,077</u>	<u>\$ 13,940</u>
Post-employment benefits	<u>189</u>	<u>160</u>
	<u>\$ 15,266</u>	<u>\$ 14,100</u>

(VI) Other related party transactions

1. Other expenses

<u>Category/Name of related party</u>	<u>January 1 to March 31, 2025</u>	<u>January 1 to March 31, 2024</u>
Joyea Co., Ltd.	<u>\$ 7</u>	<u>\$ 24</u>

This refers to repair and other related expenses incurred by the Company and its subsidiaries.

2. Starting from March 2024, the Company's key management personnel, Shih An, has gradually cancelled their joint guarantees for some of the long-term bank borrowings of the Company and its subsidiaries.

XXX. Pledged assets

The Company and its subsidiaries provided the following assets as collateral for long-term borrowings and customs duty guarantee bonds:

	<u>Book value</u>		
	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Land	\$ 705,898	\$ -	\$ -
Unfinished construction and equipment to be inspected	579,976	-	-
Other financial assets	2,287	-	-
Machinery and equipment	-	-	32,622
	<u>\$ 1,288,161</u>	<u>\$ -</u>	<u>\$ 32,622</u>

XXXI. Significant unrecognized contractual commitment

As of March 31, 2025, the Company and its subsidiaries have signed contracts for the purchase of property, plant and equipment with a total price of approximately NT\$2,143,517 thousand, of which NT\$1,312,911 thousand has not yet been recognized in the accounts.

XXXII. Significant information on assets and liabilities denominated in foreign currencies

The following information is summarized and expressed in foreign currencies other than the functional currencies of the Company and each entity. The exchange rates disclosed refer to the rates at which these foreign currencies are converted to the functional currency. Financial assets and liabilities denominated in foreign currencies with significant impact are as follows:

<u>March 31, 2025</u>	<u>Foreign currency</u>	<u>Unit: Each foreign currency in thousands</u>		
		<u>Exchange rate</u>	<u>Carrying amount</u>	
Monetary item - foreign currency assets				
USD	\$ 9,710	33.205 (USD:NTD)	\$ 322,422	
RMB	36,308	4.573 (RMB:NTD)	166,035	
JPY	13,763	0.2227 (JPY:NTD)	3,065	

(To be Continued)

(Continued from previous page)

March 31, 2025	Foreign currency	Exchange rate		Carrying amount
Non-monetary items of assets denominated in foreign currencies Subsidiaries accounted for using the equity method				
USD	\$ 1,349	33.205	(USD:NTD)	\$ 44,777
RMB	291,505	4.573	(RMB:NTD)	1,333,052
Monetary item foreign currency liabilities				
USD	517	33.205	(USD:NTD)	17,169
USD	71	7.1782	(USD:CNY)	2,320
RMB	133	4.573	(RMB:NTD)	610
December 31, 2024				
Monetary item - foreign currency assets				
USD	6,869	32.785	(USD:NTD)	225,193
RMB	50,996	4.478	(RMB:NTD)	228,361
JPY	4,469	0.2099	(JPY:NTD)	938
Non-monetary items of assets denominated in foreign currencies Subsidiaries accounted for using the equity method				
RMB	283,045	4.478	(RMB:NTD)	1,267,474
Monetary item foreign currency liabilities				
USD	798	32.785	(USD:NTD)	26,161
USD	45	7.1884	(USD:CNY)	1,451
RMB	121	4.478	(RMB:NTD)	543
JPY	2,101	0.2099	(JPY:NTD)	441

(To be Continued)

(Continued from previous page)

March 31, 2024

Monetary item - foreign
currency assets

USD	\$	5,541	32.00	(USD:NTD)	\$	177,323
RMB		52,752	4.408	(RMB:NTD)		232,532

Non-monetary items of
assets denominated in
foreign currencies
Subsidiaries accounted
for using the equity
method

RMB		242,306	4.408	(RMB:NTD)		1,068,084
-----	--	---------	-------	-----------	--	-----------

Monetary item foreign
currency liabilities

USD		385	32.00	(USD:NTD)		12,311
-----	--	-----	-------	-----------	--	--------

The Company and its subsidiaries recognized foreign exchange net gains of NT\$10,761 thousand and NT\$13,606 thousand for the periods from January 1 to March 31, 2025 and 2024, respectively. Due to the diverse functional currency types in foreign currency transactions, exchange gains and losses cannot be disclosed by each material foreign currency.

XXXIII. Disclosures in notes

(I) Significant transactions and (II) Information on investees

1. Loans to others: None.
2. Endorsements/guarantees for others: None.
3. Material holdings of marketable securities as of the period end (excluding investments in subsidiaries and associates): None.
4. Total purchases from or sales to related parties amounting to at least NT\$100 million or 20% of the paid-in capital: None.
5. Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital: None.
6. Information on investees: Please refer to Table 1.
7. Business relationships and material transactions between the parent company and its subsidiaries, as well as among the subsidiaries: Please refer to Table 3.

(II) Mainland China Investment Information

1. For information on invested companies in Mainland China, including company names, main businesses, paid-in capital, investment methods, inward/outward remittance of funds, shareholding percentages, profit/loss for the period, recognized investment gain/loss, carrying amount of investments as of the period end, repatriated investment income, and limits on investment in Mainland China, please refer to the attached Table 2.
2. Any of the following significant transactions with investee companies in mainland China, either directly or indirectly through a third party, and their prices, payment terms, and unrealized gains or losses:
 - (1) There were no purchases requiring disclosure of amounts, percentages, and ending balances of related payables.

- (2) There were no sales requiring disclosure of amounts, percentages, and ending balances of related receivables.
- (3) The amount of property transactions and the amount of the resulting gain or loss: None.
- (4) The balance and purpose of endorsements/guarantees for bills: None.
- (5) There were no financings requiring the disclosure of highest balance, ending balance, interest rate range, and total interest for the current period.
- (6) Other transactions with significant impacts on current period income or financial position, such as the rendering or receipt of services: Please refer to Table 3.

XXXIV. Department information

The information provided to the chief operating decision-maker for allocating resources and evaluating segment performance, with emphasis on each type of product or service delivered or provided. The operating segments of the Company and its subsidiaries shall be reported as follows:

- **VIZIONFOCUS**

The main business items are the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments and international trading and other consulting services.

- **Jiangsu Vizionfocus Inc.**

The main business includes R&D, design and production of contact lenses, wholesale and import and export of similar products of the above products.

- **Others** - For the subsidiaries of the consolidated entity as the operating segment, please refer to the descriptions in Note 10.

(I) Segment revenues and operating results

The revenue and operating results of the Company and its subsidiaries are analyzed by reportable segment as follows:

	VIZIONFOCUS	Jiangsu Vizionfocus Inc.	Others	Adjustments and write-offs	Consolidated
January 1 to March 31, 2025					
Revenue from customers other than the parent company and subsidiaries	\$ 561,321	\$ 234,933	\$ 14,281	\$ -	\$ 810,535
Revenue from parent company and subsidiaries	<u>40,630</u>	<u>49</u>	<u>-</u>	<u>(40,679)</u>	<u>-</u>
Total revenue	<u>\$ 601,951</u>	<u>\$ 234,982</u>	<u>\$ 14,281</u>	<u>\$ (40,679)</u>	<u>\$ 810,535</u>
Segment profit (loss)	\$ 194,361	\$ 46,310	\$ (6,616)	\$ 4,428	\$ 238,483
Interest revenue	2,137	1,247	80	-	3,464
Other income	5,818	8,801	-	(4,428)	10,191
Other gains and losses	10,848	(39)	-	-	10,809
Share of Profit (Loss) of Subsidiaries Accounted for Using the Equity Method	32,589	-	76,346	(108,935)	-
Finance Costs	<u>(4,734)</u>	<u>(1,934)</u>	<u>(7)</u>	<u>-</u>	<u>(6,675)</u>
Net income before tax	241,019	54,385	69,803	(108,935)	256,272
Income tax expense	<u>48,288</u>	<u>6,668</u>	<u>-</u>	<u>-</u>	<u>54,956</u>
Net income for the period	<u>\$ 192,731</u>	<u>\$ 47,717</u>	<u>\$ 69,803</u>	<u>\$ (108,935)</u>	<u>\$ 201,316</u>
January 1 to March 31, 2024					
Revenue from customers other than the parent company and subsidiaries	\$ 503,612	\$ 264,421	\$ -	\$ -	\$ 768,033
Revenue from parent company and subsidiaries	<u>19,195</u>	<u>1</u>	<u>-</u>	<u>(19,196)</u>	<u>-</u>
Total revenue	<u>\$ 522,807</u>	<u>\$ 264,422</u>	<u>\$ -</u>	<u>\$ (19,196)</u>	<u>\$ 768,033</u>
Segment profit	\$ 157,767	\$ 76,375	\$ -	\$ 4,973	\$ 239,115
Interest revenue	927	2,612	-	-	3,539
Other income	8,390	1,070	-	(4,973)	4,487
Other gains and losses	13,597	(51)	-	-	13,546
Share of Profit (Loss) of Subsidiaries Accounted for Using the Equity Method	54,978	-	109,956	(164,934)	-
Finance Costs	<u>(7,092)</u>	<u>(238)</u>	<u>-</u>	<u>-</u>	<u>(7,330)</u>
Net income before tax	228,567	79,768	109,956	(164,934)	253,357
Income tax expense	<u>45,738</u>	<u>11,046</u>	<u>-</u>	<u>-</u>	<u>56,784</u>
Net income for the period	<u>\$ 182,829</u>	<u>\$ 68,722</u>	<u>\$ 109,956</u>	<u>\$ (164,934)</u>	<u>\$ 196,573</u>

Departmental profit or loss refers to the profit earned by each department. This measured amount is provided to the chief operating decision-maker for allocating resources to segments and evaluating their performance.

(II) Departmental total assets and liabilities

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Segment assets</u>			
VIZIONFOCUS	\$ 5,554,126	\$ 5,190,286	\$ 5,026,239
Jiangsu Vizionfocus Inc.	2,104,830	2,049,343	1,611,114
Others	2,798,938	2,535,599	2,136,168
Adjustments and write-offs	<u>(4,114,093)</u>	<u>(3,835,517)</u>	<u>(3,230,958)</u>
Consolidated total assets	<u>\$ 6,343,801</u>	<u>\$ 5,939,711</u>	<u>\$ 5,542,563</u>
<u>Departmental liabilities</u>			
VIZIONFOCUS	\$ 1,797,624	\$ 1,657,551	\$ 1,827,050
Jiangsu Vizionfocus Inc.	438,548	465,033	276,041
Others	28,837	600	-
Adjustments and write-offs	<u>(46,407)</u>	<u>(33,070)</u>	<u>(26,732)</u>
Consolidated total liabilities	<u>\$ 2,218,602</u>	<u>\$ 2,090,114</u>	<u>\$ 2,076,359</u>

VIZIONFOCUS INC. and subsidiaries
Information on investees
January 1 to March 31, 2025

Table 1

Unit: NTD Thousand
(unless otherwise stated)

Name of Investment Company	Name of investee	Location of the area	Main business items	Initial investment amount		Held at end of period			Profit or loss for the current period of investee companies (Note)	Investment profit or loss recognized during the current period (Note)	Notes
				End of current period	End of last year	Number of shares	Percentage (%)	Carrying amount			
The Company	Green Wealth Investments Limited (Samoa)	Samoa	International investment	\$ 1,097,607	\$ 1,097,607	35,692,609	100	\$ 1,333,052	\$ 38,173	\$ 38,173	
The Company	Star Focus Inc.	Taiwan	Medical device sales	24,400	100	2,440,000	40.67	23,780	(1,477)	(601)	
The Company	Optical Connection Technology Inc.	USA	Medical device sales	49,547	-	1,500,000	98.36	44,777	(5,066)	(4,983)	
Green Wealth Investments Limited (Samoa)	Clear Precise Investments Limited (Samoa)	Samoa	International investment	1,097,607	1,097,607	35,692,609	100	1,333,052	38,173	38,173	

Note : All have been eliminated when preparing the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Mainland China Investment Information
January 1 to March 31, 2025

Table 2

Unit: NTD Thousand
(unless otherwise stated)

Name of investee company in Mainland China	Main business items	Paid-up capital	Investment method (Note 1)	Accumulated investment amount remitted from Taiwan at the beginning of current period	Investment amount remitted or recovered in the current period		Accumulated investment amount remitted from Taiwan at the end of the period	Net income of investees for the period	The Company's shareholding ratio in direct or indirect investments (%)	Investment gains recognized in current period	Book value of investment at the end of the period	Repatriated investment income up to the current period	Notes
					Remitted	Recovered							
Jiangsu Vizionfocus Inc.	R&D, design, and production of contact lens; wholesale and import and export of similar products of the above-mentioned products.	\$ 732,595	(2)	\$1,097,607	\$ -	\$ -	\$1,097,607	\$ 47,717	80	\$ 38,173	\$1,333,026	\$ -	Notes 2 & 3

Name of Investment Company	The accumulated amount remitted from Taiwan to invest in mainland China as of the end of the current period:	Amount of investment approved by the Investment Commission, Ministry of Economic Affairs	Limit of the Company's investment in Mainland China (Note 4)
Jiangsu Vizionfocus Inc.	\$ 1,097,607	\$ 1,184,248	\$ -

Note 1: Investment methods are divided into the following three types. It is sufficient to indicate the type of investment:

- (1) Direct investment in Mainland China.
- (2) Reinvest in Mainland China through a company in a third region.
- (3) Any other means.

Note 2: All have been eliminated when preparing the consolidated financial statements.

Note 3: Recognized and disclosed based on the Company's reviewed financial statements by its certified public accountants.

Note 4: This is in accordance with Point 3 of the "Principles for Reviewing Investments or Technical Cooperation in Mainland China," revised and issued on August 29, 2008, under Order Jing-Shen-Zi No. 09704604680. Our company has obtained a certificate from the Industrial Development Bureau of the Ministry of Economic Affairs, confirming compliance with the operational scope required for headquarters, thereby exempting it from any upper limits on investments in Mainland China.

VIZIONFOCUS INC. and subsidiaries
 Business relationships and material transactions between the parent company and its subsidiaries
 January 1 to March 31, 2025

Table 3

Unit: NTD Thousand
 (unless otherwise stated)

Serial number	Trader's Name	Trading counterpart	Relationship with the counterparty	Transactions with each other			As a percentage of consolidated revenue or total assets (%)
				Subject Matters	Amount	Trading terms and conditions	
0	The Company	Jiangsu Vizionfocus Inc.	Subsidiary	Service revenue	\$ 15,647	As stipulated in the contract	1.93
0	The Company	Jiangsu Vizionfocus Inc.	Subsidiary	Other operating revenue	6,510	As stipulated in the contract	0.80
0	The Company	Jiangsu Vizionfocus Inc.	Subsidiary	Royalty income	4,428	As stipulated in the contract	0.55
0	The Company	Jiangsu Vizionfocus Inc.	Subsidiary	Accounts receivable	22,462	As stipulated in the contract	0.35
0	The Company	Star Focus Inc.	Subsidiary	Sales revenue	13,662	As stipulated in the contract	1.69
0	The Company	Star Focus Inc.	Subsidiary	Accounts receivable	14,350	As stipulated in the contract	0.23
0	The Company	Optical Connection Technology Inc.	Subsidiary	Sales revenue	4,807	As stipulated in the contract	0.59
0	The Company	Optical Connection Technology Inc.	Subsidiary	Accounts receivable	4,866	As stipulated in the contract	0.08